↓ Skip to main content

Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study

Overview of attention for article published in The Lancet Gastroenterology & Hepatology, May 2024
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (97th percentile)
  • High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

twitter
139 X users

Citations

dimensions_citation
10 Dimensions

Readers on

mendeley
17 Mendeley